Cocrystal Pharma, Inc. (COCP)
Nasdaq: COCP · Pharmaceutical Preparations · Bothell, WA · filing with the SEC since 2007
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 31, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 29, 2023 | Mar 23, 2022 | Mar 17, 2021 | Mar 27, 2020 | Apr 1, 2019 | Mar 21, 2018 | Mar 31, 2017 |
| Revenue | · | · | · | · | · | 2,014 | 6,564 | · | · | · |
| For lenders | ||||||||||
| Interest and dividend income | · | · | · | · | · | · | · | · | -7 | 126 |
| Net interest income | · | · | · | · | · | · | -19 | -58 | -7 | · |
| Research and development | 5,055 | 12,537 | 15,169 | 12,392 | 8,794 | 6,034r | 4,004 | 4,667r | 5,822 | 101,679 |
| General and administrative | 3,964 | 5,341 | 5,990 | 5,745 | 5,427 | 5,566r | 4,863 | 4,352 | 2,440 | 4,140 |
| Total operating expenses | 9,019 | 17,878 | 18,559 | 38,829 | 14,221 | 11,600 | 54,970 | 62,924 | 8,262 | 105,819 |
| Total costs and expenses | · | 2,200 | 3,050 | · | · | · | · | · | · | · |
| Operating income | -9,019 | -17,878 | -18,559 | -38,829 | -14,221 | -9,586 | -48,406 | -62,924 | -8,262 | -105,819 |
| Interest expense | -134 | -537 | -640 | 2 | 4 | 8 | 19 | 58 | · | · |
| Other income (expense), net | · | · | · | · | · | · | · | · | · | 1,551 |
| Total non-operating income (expense) | 188 | 374 | 575 | -8 | 36 | -62 | 237 | 294 | 769 | 1,551 |
| Income before income taxes | -8,831 | -18,627 | · | · | · | -9,648 | -48,169 | -62,630 | -7,493 | -104,268 |
| Income tax expense | · | · | · | · | · | · | · | -13,582 | -6,880 | -29,394 |
| Net income | -8,831 | -17,504 | -17,984 | -38,837 | -14,185 | -9,648 | -48,169 | -49,048 | -613 | -74,874 |
| Net income to common shareholders | · | · | · | · | · | · | -48,169 | -49,048 | -613 | · |
| Earnings per share, basic | -0.78 | -1.72 | -1.87 | -4.77 | -0.16 | · | · | · | -0.03 | -3.18r |
| Earnings per share, diluted | -0.78 | -1.72 | -1.87 | -4.77 | · | · | · | · | -0.03 | -3.30r |
| Earnings per share, basic and diluted | · | · | · | · | -0.16 | -0.17 | -1.51 | -1.75 | -0.03 | · |
| Weighted average shares, basic | 11,290,000 | 10,174,000 | 9,651,000 | 8,143,000 | 7,364,000 | · | 31,859,000b | 28,009,000rb | 24,126,000 | 23,518,000r |
| Weighted average shares, diluted | 11,290,000 | 10,174,000 | 9,651,000 | 8,143,000 | · | · | · | · | 24,126,000 | 23,533,000r |
| Weighted average shares, basic and diluted | · | · | · | · | 88,368,000 | 55,217,000r | 31,859 | 28,009r | 24,126,000 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-30 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxInterest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingNet interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted